// App-Quantinova.ai

BSH19‐OR‐025 : Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Researchers

Presenter

  • T. Munir

Principal Investigators

  • A. Rawstron

  • K. Brock

  • S. Munoz Vicente

  • F. Yates

  • R. Bishop

  • D. Macdonald

  • C. Fegan

  • A. McCaig

  • A. Schuh

  • A. Pettitt

  • J.G. Gribben

  • P.E. Patten

  • S. Devereux

  • A. Bloor

  • C.P. Fox

  • F. Forconi

  • P. Hillmen

Medical Centers

  • St James's Institute of Oncology, Leeds Teaching Hospital

  • St James's institute of Oncology, Leeds

  • University of Birmingham, Institute of Cancer and Genomic Sciences, Cancer Research UK Clinical Trials Unit

  • University of Birmingham, Institute of Cancer and Genomic Sciences, Cancer Research UK Clinical Trials Unit

  • Imperial College Healthcare NHS Trust, London,

  • Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff

  • The Beatson, West of Scotland Cancer Centre, Glasgow,

  • Oxford University Hospitals NHS Trust, Oxford,

  • Haematology, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool

  • Barts Health NHS Trust

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • The Christie NHS Foundation Trust, Manchester,

  • Nottingham University Hospitals NHS Trust, Nottingham,

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

  • Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Blood/haematological Diseases

  • Central Nervous System (CNS)

  • Genetic Disorder

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Neutropenia

  • Pemphigus

  • Mental retardation, autosomal dominant 4

  • Mental retardation, autosomal dominant 5

Biomarkers

  • Bruton tyrosine kinase

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • Idelalisib

  • Venetoclax

  • Ibrutinib

  • Rituximab

  • Insulin tregopil

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved